Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer

Timothy F. Burns, Irina Dobromilskaya, Sara C. Murphy, Rajendra P. Gajula, Saravanan Thiyagarajan, Sarah N.H. Chatley, Khaled Aziz, Yoon-Jae Cho, Phuoc T. Tran, Charles M. Rudin

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

A large fraction of non-small cell lung cancers (NSCLC) are dependent on defined oncogenic driver mutations. Although targeted agents exist for EGFR- and EML4-ALK-driven NSCLCs, no therapies target the most frequently found driver mutation, KRAS. Furthermore, acquired resistance to the currently targetable driver mutations is nearly universally observed. Clearly a novel therapeutic approach is needed to target oncogene-driven NSCLCs.We recently showed that the basic helix-loop-helix transcription factor Twist1 cooperates with mutant Kras to induce lung adenocarcinoma in transgenic mouse models and that inhibition of Twist1 in these models led to Kras-induced senescence. In the current study, we examine the role of TWIST1 in oncogene-driven human NSCLCs. Silencing of TWIST1 in KRAS-mutant human NSCLC cell lines resulted in dramatic growth inhibition and either activation of a latent oncogene-induced senescence program or, in some cases, apoptosis. Similar effects were observed in EGFR mutation-driven and c-Met-amplified NSCLC cell lines. Growth inhibition by silencing of TWIST1 was independent of p53 or p16 mutational status and did not require previously defined mediators of senescence, p21 and p27, nor could this phenotype be rescued by overexpression of SKP2. In xenograft models, silencing of TWIST1 resulted in significant growth inhibition of KRAS-mutant, EGFR-mutant, and c-Met-amplified NSCLCs. Remarkably, inducible silencing of TWIST1 resulted in significant growth inhibition of established KRAS-mutant tumors. Together these findings suggest that silencing of TWIST1 in oncogene driver-dependent NSCLCs represents a novel and promising therapeutic strategy.

Original languageEnglish (US)
Pages (from-to)329-338
Number of pages10
JournalMolecular Cancer Research
Volume11
Issue number4
DOIs
StatePublished - Apr 1 2013
Externally publishedYes

Fingerprint

Oncogenes
Non-Small Cell Lung Carcinoma
Mutation
Growth
Basic Helix-Loop-Helix Transcription Factors
Cell Line
Heterografts
Transgenic Mice
Therapeutics
Apoptosis
Phenotype
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Burns, T. F., Dobromilskaya, I., Murphy, S. C., Gajula, R. P., Thiyagarajan, S., Chatley, S. N. H., ... Rudin, C. M. (2013). Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer. Molecular Cancer Research, 11(4), 329-338. https://doi.org/10.1158/1541-7786.MCR-12-0456

Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer. / Burns, Timothy F.; Dobromilskaya, Irina; Murphy, Sara C.; Gajula, Rajendra P.; Thiyagarajan, Saravanan; Chatley, Sarah N.H.; Aziz, Khaled; Cho, Yoon-Jae; Tran, Phuoc T.; Rudin, Charles M.

In: Molecular Cancer Research, Vol. 11, No. 4, 01.04.2013, p. 329-338.

Research output: Contribution to journalArticle

Burns, TF, Dobromilskaya, I, Murphy, SC, Gajula, RP, Thiyagarajan, S, Chatley, SNH, Aziz, K, Cho, Y-J, Tran, PT & Rudin, CM 2013, 'Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer', Molecular Cancer Research, vol. 11, no. 4, pp. 329-338. https://doi.org/10.1158/1541-7786.MCR-12-0456
Burns, Timothy F. ; Dobromilskaya, Irina ; Murphy, Sara C. ; Gajula, Rajendra P. ; Thiyagarajan, Saravanan ; Chatley, Sarah N.H. ; Aziz, Khaled ; Cho, Yoon-Jae ; Tran, Phuoc T. ; Rudin, Charles M. / Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer. In: Molecular Cancer Research. 2013 ; Vol. 11, No. 4. pp. 329-338.
@article{c592a05169404961a1d8fec3f05d3784,
title = "Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer",
abstract = "A large fraction of non-small cell lung cancers (NSCLC) are dependent on defined oncogenic driver mutations. Although targeted agents exist for EGFR- and EML4-ALK-driven NSCLCs, no therapies target the most frequently found driver mutation, KRAS. Furthermore, acquired resistance to the currently targetable driver mutations is nearly universally observed. Clearly a novel therapeutic approach is needed to target oncogene-driven NSCLCs.We recently showed that the basic helix-loop-helix transcription factor Twist1 cooperates with mutant Kras to induce lung adenocarcinoma in transgenic mouse models and that inhibition of Twist1 in these models led to Kras-induced senescence. In the current study, we examine the role of TWIST1 in oncogene-driven human NSCLCs. Silencing of TWIST1 in KRAS-mutant human NSCLC cell lines resulted in dramatic growth inhibition and either activation of a latent oncogene-induced senescence program or, in some cases, apoptosis. Similar effects were observed in EGFR mutation-driven and c-Met-amplified NSCLC cell lines. Growth inhibition by silencing of TWIST1 was independent of p53 or p16 mutational status and did not require previously defined mediators of senescence, p21 and p27, nor could this phenotype be rescued by overexpression of SKP2. In xenograft models, silencing of TWIST1 resulted in significant growth inhibition of KRAS-mutant, EGFR-mutant, and c-Met-amplified NSCLCs. Remarkably, inducible silencing of TWIST1 resulted in significant growth inhibition of established KRAS-mutant tumors. Together these findings suggest that silencing of TWIST1 in oncogene driver-dependent NSCLCs represents a novel and promising therapeutic strategy.",
author = "Burns, {Timothy F.} and Irina Dobromilskaya and Murphy, {Sara C.} and Gajula, {Rajendra P.} and Saravanan Thiyagarajan and Chatley, {Sarah N.H.} and Khaled Aziz and Yoon-Jae Cho and Tran, {Phuoc T.} and Rudin, {Charles M.}",
year = "2013",
month = "4",
day = "1",
doi = "10.1158/1541-7786.MCR-12-0456",
language = "English (US)",
volume = "11",
pages = "329--338",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer

AU - Burns, Timothy F.

AU - Dobromilskaya, Irina

AU - Murphy, Sara C.

AU - Gajula, Rajendra P.

AU - Thiyagarajan, Saravanan

AU - Chatley, Sarah N.H.

AU - Aziz, Khaled

AU - Cho, Yoon-Jae

AU - Tran, Phuoc T.

AU - Rudin, Charles M.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - A large fraction of non-small cell lung cancers (NSCLC) are dependent on defined oncogenic driver mutations. Although targeted agents exist for EGFR- and EML4-ALK-driven NSCLCs, no therapies target the most frequently found driver mutation, KRAS. Furthermore, acquired resistance to the currently targetable driver mutations is nearly universally observed. Clearly a novel therapeutic approach is needed to target oncogene-driven NSCLCs.We recently showed that the basic helix-loop-helix transcription factor Twist1 cooperates with mutant Kras to induce lung adenocarcinoma in transgenic mouse models and that inhibition of Twist1 in these models led to Kras-induced senescence. In the current study, we examine the role of TWIST1 in oncogene-driven human NSCLCs. Silencing of TWIST1 in KRAS-mutant human NSCLC cell lines resulted in dramatic growth inhibition and either activation of a latent oncogene-induced senescence program or, in some cases, apoptosis. Similar effects were observed in EGFR mutation-driven and c-Met-amplified NSCLC cell lines. Growth inhibition by silencing of TWIST1 was independent of p53 or p16 mutational status and did not require previously defined mediators of senescence, p21 and p27, nor could this phenotype be rescued by overexpression of SKP2. In xenograft models, silencing of TWIST1 resulted in significant growth inhibition of KRAS-mutant, EGFR-mutant, and c-Met-amplified NSCLCs. Remarkably, inducible silencing of TWIST1 resulted in significant growth inhibition of established KRAS-mutant tumors. Together these findings suggest that silencing of TWIST1 in oncogene driver-dependent NSCLCs represents a novel and promising therapeutic strategy.

AB - A large fraction of non-small cell lung cancers (NSCLC) are dependent on defined oncogenic driver mutations. Although targeted agents exist for EGFR- and EML4-ALK-driven NSCLCs, no therapies target the most frequently found driver mutation, KRAS. Furthermore, acquired resistance to the currently targetable driver mutations is nearly universally observed. Clearly a novel therapeutic approach is needed to target oncogene-driven NSCLCs.We recently showed that the basic helix-loop-helix transcription factor Twist1 cooperates with mutant Kras to induce lung adenocarcinoma in transgenic mouse models and that inhibition of Twist1 in these models led to Kras-induced senescence. In the current study, we examine the role of TWIST1 in oncogene-driven human NSCLCs. Silencing of TWIST1 in KRAS-mutant human NSCLC cell lines resulted in dramatic growth inhibition and either activation of a latent oncogene-induced senescence program or, in some cases, apoptosis. Similar effects were observed in EGFR mutation-driven and c-Met-amplified NSCLC cell lines. Growth inhibition by silencing of TWIST1 was independent of p53 or p16 mutational status and did not require previously defined mediators of senescence, p21 and p27, nor could this phenotype be rescued by overexpression of SKP2. In xenograft models, silencing of TWIST1 resulted in significant growth inhibition of KRAS-mutant, EGFR-mutant, and c-Met-amplified NSCLCs. Remarkably, inducible silencing of TWIST1 resulted in significant growth inhibition of established KRAS-mutant tumors. Together these findings suggest that silencing of TWIST1 in oncogene driver-dependent NSCLCs represents a novel and promising therapeutic strategy.

UR - http://www.scopus.com/inward/record.url?scp=84876521231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876521231&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-12-0456

DO - 10.1158/1541-7786.MCR-12-0456

M3 - Article

C2 - 23364532

AN - SCOPUS:84876521231

VL - 11

SP - 329

EP - 338

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 4

ER -